JP2021500852A - 共有抗原を標的にする抗原結合タンパク質 - Google Patents

共有抗原を標的にする抗原結合タンパク質 Download PDF

Info

Publication number
JP2021500852A
JP2021500852A JP2020509107A JP2020509107A JP2021500852A JP 2021500852 A JP2021500852 A JP 2021500852A JP 2020509107 A JP2020509107 A JP 2020509107A JP 2020509107 A JP2020509107 A JP 2020509107A JP 2021500852 A JP2021500852 A JP 2021500852A
Authority
JP
Japan
Prior art keywords
seq
hla
sequence
antigen
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020509107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500852A5 (https=
Inventor
カリン ジュース
カリン ジュース
ウェイド ブレア
ウェイド ブレア
ブレンダン ブリク−スリバン
ブレンダン ブリク−スリバン
ジェニファー バスビー
ジェニファー バスビー
ミシェル アン バスビー
ミシェル アン バスビー
モイカ スコベルン
モイカ スコベルン
ローマン ヤレンスカイ
ローマン ヤレンスカイ
ジョシュア マイケル フランシス
ジョシュア マイケル フランシス
ヘイスベルト マーニックス グロテンブレグ
ヘイスベルト マーニックス グロテンブレグ
Original Assignee
グリットストーン オンコロジー インコーポレイテッド
グリットストーン オンコロジー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリットストーン オンコロジー インコーポレイテッド, グリットストーン オンコロジー インコーポレイテッド filed Critical グリットストーン オンコロジー インコーポレイテッド
Publication of JP2021500852A publication Critical patent/JP2021500852A/ja
Publication of JP2021500852A5 publication Critical patent/JP2021500852A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
JP2020509107A 2017-08-18 2018-08-17 共有抗原を標的にする抗原結合タンパク質 Pending JP2021500852A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762547146P 2017-08-18 2017-08-18
US62/547,146 2017-08-18
US201762581368P 2017-11-03 2017-11-03
US62/581,368 2017-11-03
PCT/US2018/046997 WO2019036688A1 (en) 2017-08-18 2018-08-17 ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Publications (2)

Publication Number Publication Date
JP2021500852A true JP2021500852A (ja) 2021-01-14
JP2021500852A5 JP2021500852A5 (https=) 2021-09-30

Family

ID=65362959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020509107A Pending JP2021500852A (ja) 2017-08-18 2018-08-17 共有抗原を標的にする抗原結合タンパク質

Country Status (12)

Country Link
US (2) US20210147550A1 (https=)
EP (1) EP3668539A4 (https=)
JP (1) JP2021500852A (https=)
KR (2) KR20200084320A (https=)
CN (2) CN111328288B (https=)
AU (1) AU2018318303A1 (https=)
CA (1) CA3072816A1 (https=)
IL (1) IL272466A (https=)
MX (2) MX2020001879A (https=)
SG (1) SG11202001368SA (https=)
WO (1) WO2019036688A1 (https=)
ZA (1) ZA202001285B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522459A (ja) * 2022-06-14 2025-07-15 上海▲ビン▼鐵生物科技有限責任公司 Ｋｒａｓ ｇ１２ｖ突然変異ポリペプチドを標的するｔ細胞受容体及びその用途

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102643923B1 (ko) 2014-12-23 2024-03-05 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
CN112236447B (zh) * 2018-04-19 2023-10-20 得克萨斯州大学系统董事会 具有mage-b2特异性的t细胞受体及其用途
IL280890B2 (en) * 2018-08-17 2025-10-01 Gritstone Bio Inc Antigen-binding protein that targets shared antigens
CN111138521B (zh) * 2018-11-06 2022-10-28 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN111138522B (zh) * 2018-11-06 2023-01-24 香雪生命科学技术（广东）有限公司 衍生自afp的肿瘤抗原短肽
WO2020172332A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
WO2020191365A1 (en) 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
SG11202110956RA (en) 2019-04-05 2021-10-28 Rootpath Genomics Inc Compositions and methods for t-cell receptor gene assembly
EP3962939A4 (en) * 2019-05-03 2023-05-17 Gigamune, Inc. MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
WO2021005108A1 (en) * 2019-07-09 2021-01-14 Medigene Immunotherapies Gmbh Magea10 specific t cell receptors and their use
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
CN112300261B (zh) * 2019-07-23 2023-03-17 香雪生命科学技术（广东）有限公司 一种衍生自afp的肿瘤抗原短肽
TW202124437A (zh) * 2019-08-19 2021-07-01 美商潘迪恩營運公司 以ｐｄ－１促效劑進行之標靶免疫耐受性
WO2021048381A1 (en) * 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying stable mhc binding peptides using mass spectrometry
US20220372092A1 (en) * 2019-10-18 2022-11-24 Board Of Regents, The University Of Texas System Hla-restricted vcx/y peptides and t cell receptors and use thereof
WO2021092094A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
AU2020384374A1 (en) * 2019-11-15 2022-06-09 Seattle Project Corp. Antigen-binding proteins targeting shared neoantigens
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN115785254A (zh) * 2019-12-13 2023-03-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
CN113072636B (zh) * 2020-01-06 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体及其编码序列
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN113321727B (zh) * 2020-02-28 2024-04-09 香雪生命科学技术（广东）有限公司 一种识别afp抗原短肽的t细胞受体及其编码序列
CN113321725B (zh) * 2020-02-28 2024-06-11 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体
KR20240096884A (ko) * 2020-03-10 2024-06-26 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
US11896619B2 (en) * 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
CN113493505A (zh) * 2020-03-20 2021-10-12 香雪生命科学技术（广东）有限公司 识别afp抗原的高亲和力tcr
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
CN116096740A (zh) * 2020-06-09 2023-05-09 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
JP7391208B2 (ja) 2020-07-08 2023-12-04 エルジー エナジー ソリューション リミテッド バッテリーパック及びそれを含む自動車
EP4188962A4 (en) * 2020-07-29 2025-01-01 Gritstone bio, Inc. MANIPULATED MULTI-SPECIFIC ANTIBODIES AND RELATED METHODS OF USE AND PRODUCTION
EP4208473A2 (en) * 2020-09-04 2023-07-12 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing r273c or y220c mutations in p53
WO2022063966A1 (en) * 2020-09-24 2022-03-31 Medigene Immunotherapies Gmbh Prame specific t-cell receptors and uses thereof
CN116615446A (zh) * 2020-09-24 2023-08-18 基因医疗免疫疗法有限责任公司 Mage-a3特异性t细胞受体及其用途
WO2022087380A1 (en) * 2020-10-23 2022-04-28 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor identification
JP2023548556A (ja) * 2020-11-05 2023-11-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｅｇｆｒ抗原を標的とする操作されたｔ細胞受容体および使用方法
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
EP4277925A4 (en) * 2021-01-14 2025-06-11 Gritstone bio, Inc. Multispecific antibodies and methods of use
EP4294831A1 (en) * 2021-02-16 2023-12-27 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against cd22
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
US20240293459A1 (en) * 2021-03-29 2024-09-05 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting sars-cov-2 antigens and methods of use
EP4320144A4 (en) * 2021-04-05 2025-04-09 Janssen Biotech, Inc. T CELL RECEPTORS CALR AND JAK2
CA3216276A1 (en) 2021-04-29 2022-11-03 Yardena Samuels T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
EP4347639A4 (en) * 2021-05-25 2025-08-06 Memorial Sloan Kettering Cancer Center T CELL RECEPTORS TARGETING RAS MUTATIONS AND THEIR USES
CA3227687A1 (en) * 2021-08-06 2023-02-09 Marc Andrew GILLIG Process for producing personalized cancer immunotherapy
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CA3244259A1 (en) * 2022-02-23 2023-08-31 Aloe Therapeutics Inc Compositions and methods for modulating the immune system
NL2031118B1 (en) * 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
EP4598569A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN116158405B (zh) * 2023-01-30 2024-04-26 西北农林科技大学 一种提高奶山羊后代母羔率的方法
WO2025064738A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025093596A2 (en) * 2023-10-30 2025-05-08 T-Knife Gmbh Antigen recognizing construct capable of binding to a preferentially expressed antigen in melanoma (prame) peptide and a t cell receptor (tcr) having antigenic specificity for prame as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506058A (ja) * 2001-06-19 2005-03-03 テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド 癌の治療に特に有用な免疫擬装の方法及び薬学的組成物
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
ES2834070T3 (es) * 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
EP2819702A4 (en) * 2012-02-29 2015-05-20 Ambrx Inc NOVEL PRODRUGS WITH MOLECULE COMPOSITIONS AND ITS USES
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TW201702272A (zh) * 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
GB201520559D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506058A (ja) * 2001-06-19 2005-03-03 テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド 癌の治療に特に有用な免疫擬装の方法及び薬学的組成物
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLAUDIA PARET ET AL.: "CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.", ONCOTARGET, vol. 6, no. 28, JPN6022030669, 29 July 2015 (2015-07-29), pages 25356 - 25367, ISSN: 0005013829 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522459A (ja) * 2022-06-14 2025-07-15 上海▲ビン▼鐵生物科技有限責任公司 Ｋｒａｓ ｇ１２ｖ突然変異ポリペプチドを標的するｔ細胞受容体及びその用途

Also Published As

Publication number Publication date
US20210147550A1 (en) 2021-05-20
ZA202001285B (en) 2021-08-25
KR20200084320A (ko) 2020-07-10
WO2019036688A1 (en) 2019-02-21
CN121517566A (zh) 2026-02-13
SG11202001368SA (en) 2020-03-30
AU2018318303A1 (en) 2020-04-09
KR20250040097A (ko) 2025-03-21
EP3668539A4 (en) 2021-08-18
CN111328288A (zh) 2020-06-23
MX2025011582A (es) 2025-11-03
CN111328288B (zh) 2025-11-07
CA3072816A1 (en) 2019-02-21
US20230382997A1 (en) 2023-11-30
IL272466A (en) 2020-03-31
EP3668539A1 (en) 2020-06-24
MX2020001879A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
TWI837109B (zh) 靶向共有抗原之抗原結合蛋白
US20230382997A1 (en) Antigen-binding proteins targeting shared antigens
CN112739375B (zh) 靶向共同抗原的抗原结合蛋白
US20220162320A1 (en) Multispecific binding proteins
WO2022026772A1 (en) Engineered multi-specific antibodies and related methods of use and manufacture

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230315